Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have rapidly become a cornerstone in the management of type 2 diabetes and obesity.
As their use expands globally, attention has shifted toward understanding their broader safety profile—including rare but potentially serious ocular complications.
And with that in mind ...
A new global observational analysis published in the British Journal of Ophthalmology evaluated reports of ischemic optic neuropathy (ION) associated with semaglutide and related therapies.
The findings suggest that certain formulations—particularly higher-dose injectable options—may be associated with a stronger signal for ION, raising important questions about dose, delivery method and patient risk factors.
Let’s start with the basics: What is ION and how is it linked to GLP-1 drugs?
Ischemic optic neuropathy (ION) is a vision-threatening condition caused by insufficient blood flow to the optic nerve. This disruption can lead to sudden, often irreversible vision loss in one or both eyes.
Although relatively rare, ION has recently been linked to medications that may influence vascular regulation or systemic hemodynamics.
GLP-1 receptor agonists, particularly semaglutide, have come under investigation due to their effects on weight loss, blood pressure and fluid balance—factors that could theoretically impact optic nerve perfusion.
Why have GLP-1 receptor agonists come under scrutiny for ocular safety?
The growing use of GLP-1RAs has been accompanied by increasing reports of ocular adverse events, including ION. These medications are now widely prescribed not only for diabetes but also for obesity and cardiovascular risk reduction, significantly expanding patient exposure.
Recent pharmacovigilance signals and case reports have raised concerns about potential vision-related side effects, particularly with semaglutide formulations such as Wegovy and Ozempic.
While these events remain uncommon, their severity has prompted closer investigation into whether certain drug formulations or dosing strategies may carry higher risk.
So where does this new research come in?
To better understand whether specific GLP-1 therapies are associated with ION, researchers conducted a large-scale observational analysis using real-world safety data. The goal was to evaluate whether risk signals differed by drug formulation, dose and patient characteristics—areas that had not been fully explored in previous studies.
How was the study designed?
The investigators performed a global pharmacovigilance analysis using data from the FDA Adverse Event Reporting System (FAERS) spanning 2017 to 2024.
Rather than enrolling patients prospectively, the study analyzed reported adverse events linked to GLP-1 receptor agonists, using statistical methods to identify disproportionate reporting signals. Reporting odds ratios (RORs) and adjusted analyses were used to assess whether certain drugs were more strongly associated with ION compared with others.
Who was included in the analysis?
The dataset included more than 30 million adverse event reports, of which 31,774 were associated with semaglutide.
Among these:
- Reports involved patients with an average age in the mid-50s
- Slightly more than half of the cases occurred in women
- Data included multiple semaglutide formulations, including Wegovy, Ozempic and Rybelsus
The analysis also incorporated comparator medications, such as metformin, insulin and tirzepatide, to better contextualize the observed safety signals.
What did the researchers find about ION risk?
The analysis identified a statistically significant association between semaglutide use and reported cases of ischemic optic neuropathy.
Among the different formulations, Wegovy demonstrated the strongest signal, with substantially higher reporting odds compared with Ozempic and other semaglutide products.
Importantly, no signal for ION was detected with the oral formulation Rybelsus or with comparator drugs, suggesting that the association may not apply uniformly across all GLP-1 therapies.
Did risk vary by drug type, dose or patient characteristics?
Yes; one of the most notable findings was the variation in risk depending on formulation, dose and sex.
- Higher-dose injectable semaglutide (Wegovy) was associated with the strongest signal for ION, while lower-dose or orally administered formulations showed weaker or absent associations.
- Sex-based differences were also observed, with men demonstrating a higher relative risk compared with women.
These findings point toward a potential dose- and exposure-dependent relationship, where greater systemic drug levels may contribute to increased vulnerability.
What mechanisms might explain the link between GLP-1 drugs and optic nerve injury?
Although causality has not been established, several biological mechanisms have been proposed.
High-dose GLP-1 therapy may lead to rapid metabolic changes, fluid shifts and reductions in blood pressure, including nocturnal hypotension. These effects could reduce blood flow to the optic nerve, increasing the risk of ischemic injury.
- Additionally, rapid glycemic improvements may alter vascular autoregulation, potentially making the optic nerve more susceptible to hypoperfusion.
Differences in drug absorption and systemic exposure between injectable and oral formulations may further explain why risk appears to vary across therapies.
Any limitations to consider when interpreting the findings?
As a pharmacovigilance study, the analysis is subject to several important limitations.
FAERS data rely on voluntary reporting, which can introduce reporting bias and does not allow for determination of true incidence rates.
- The database also lacks detailed clinical information, including comorbidities, disease severity and treatment duration, making it difficult to control for confounding factors.
- Additionally, increased media attention or regulatory scrutiny may influence reporting patterns, potentially amplifying certain signals.
How do these findings compare with previous research?
These results build on a growing body of literature suggesting a possible link between GLP-1 receptor agonists and ocular complications.
Prior reports have identified associations between semaglutide and optic nerve or retinal events, but this study is among the first to demonstrate differences based on formulation, dose and sex.
- The findings also align with earlier observations that injectable therapies, particularly at higher doses, may carry different safety profiles compared with oral alternatives.
Why might this matter for clinical practice and prescribing decisions?
As GLP-1 therapies continue to gain widespread use, understanding potential safety signals becomes increasingly important.
While ION remains a rare complication, its potential severity underscores the need for careful patient selection and monitoring.
Clinicians may need to consider individual risk factors, dosing strategies and formulation choices when prescribing these medications, particularly for patients who may already be at risk for vascular or optic nerve disorders.
Take home.
This large pharmacovigilance analysis suggests that semaglutide—particularly higher-dose injectable formulations—may be associated with an increased risk of ischemic optic neuropathy.
Although causation has not been established, the findings highlight a potential dose- and formulation-dependent safety signal that warrants further investigation.
- As use of GLP-1 receptor agonists continues to expand, ongoing research will be essential to clarify risk and guide safe clinical use.